Home » Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine

Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine

November 5, 2013

U.S.-based biopharmaceutical company Nanotherapeutics has started enrollment of first patient in a Phase II cervical cancer trial for Triapine, a ribonucleotidereductase inhibitor.
Pharmaceutical Business Review

19Aug
Maintaining Your Risk-Based Cleaning and Disinfectant Programs
19Aug
The True Problem of COVID-19 Misinformation: How the Spread of Inaccurate Information Harms our Progress Toward New Therapies
20Aug
Transforming Quality Management? Think Harmonizing Quality Processes First
20Aug
Implementing the IMDRF Codes: Essential Adverse Event Reporting Changes
17Sep
Spreadsheet Validation: Best Practices to Maintain Compliance
23Sep
Data Integrity in the COVID-19 Era and Beyond — Part II: Key Issues in Data Integrity: Today and Tomorrow

Nanotherapeutics Begins Patient Enrollment in Phase II Trial of Triapine

Upcoming Events

Maintaining Your Risk-Based Cleaning and Disinfectant Programs

The True Problem of COVID-19 Misinformation: How the Spread of Inaccurate Information Harms our Progress Toward New Therapies

Transforming Quality Management? Think Harmonizing Quality Processes First

Implementing the IMDRF Codes: Essential Adverse Event Reporting Changes

Spreadsheet Validation: Best Practices to Maintain Compliance

Data Integrity in the COVID-19 Era and Beyond — Part II: Key Issues in Data Integrity: Today and Tomorrow

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Moderna Lands $1.5 Billion Vaccine Contract from Operation Warp Speed

Medtronic Buys Up Manufacturer of Smart Insulin Pen

mAbxience to Produce AstraZeneca’s COVID-19 Vaccine for Latin America

Ender Diagnostics Earns CE Mark for COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements